A-prexa — Competitive Intelligence Brief

A-prexa (A-prexa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

marketed Atypical antipsychotic D2 receptor Psychiatry Small molecule

Target snapshot

A-prexa (A-prexa) — HK inno.N Corporation. A-prexa is an antipsychotic medication that works by blocking dopamine receptors in the brain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
A-prexa TARGET	A-prexa	HK inno.N Corporation	marketed	Atypical antipsychotic	D2 receptor
IM aripiprazole once monthly	IM aripiprazole once monthly	University of Utah	marketed	Atypical antipsychotic	Dopamine D2 receptor, Dopamine D3 receptor
Raclopride C11	Raclopride C11	University of North Carolina, Chapel Hill	marketed	Dopamine D2/D3 receptor antagonist (PET imaging agent)	Dopamine D2 receptor, Dopamine D3 receptor
Aripiprazole/Escitalopram combination	Aripiprazole/Escitalopram combination	Massachusetts General Hospital	marketed	Atypical antipsychotic and selective serotonin reuptake inhibitor combination	Dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor (partial agonist), serotonin transporter (SERT inhibitor)
Aripiprazole or Perphenazine	Aripiprazole or Perphenazine	Johns Hopkins University	marketed	Atypical antipsychotic (aripiprazole); Typical antipsychotic (perphenazine)	Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); Dopamine D2 receptor (perphenazine)
venlafaxine XR plus aripiprazole	venlafaxine XR plus aripiprazole	University of Pittsburgh	marketed	SNRI plus atypical antipsychotic combination	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine D2 receptor
Any FDA approved antipsychotic agent	Any FDA approved antipsychotic agent	Vanguard Research Group	marketed	Antipsychotic (dopamine antagonist)	Dopamine D2 receptor (primary); serotonin 5-HT2A receptor and others (varies by agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

1. Shanghai Mental Health Center · 10 drugs in this class
2. AstraZeneca · 6 drugs in this class
3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
5. Eli Lilly and Company · 4 drugs in this class
6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
7. Medical University of Vienna · 2 drugs in this class
8. Organon and Co · 2 drugs in this class
9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
10. H. Lundbeck A/S · 2 drugs in this class